Arthur Stril profile page

Arthur Stril is chief business officer and interim chief financial officer and member of the Executive Committee of Cellectis, a clinical-stage immuno-oncology biotech developing gene-edited allogeneic CAR T cells and in vivo gene therapies, where he leads the finance, investor relations and business development functions. Arthur began his career at the European Commission’s Directorate-General for Competition, controlling global pharmaceutical mergers. He later became head of the Hospital Financing Unit at the French Ministry of Health.